Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2002

View Archived Issues

Phase I trial initiated for HER-2 vaccine for breast cancer

Aradigm and geneRx+ collaborate on pulmonary-delivered gene therapeutics

Enrollment completed in phase IIA kidney transplantation trial of ISA-247

Novel PPARalpha agonists under study at Pfizer

Mercian and Eisai describe the isolation of new antiangiogenic agents from fungal cultures

ChondroGene and Pfizer enter osteoarthritis collaboration

BMS patent covers novel anti-HIV agents

Merck scientists present two series of thrombin inhibitors

InterMune and Inhale to develop PEGylated Infergen

EP4 receptor modulators and their use in neuropathic pain

New inhibitors of advanced glycation end products reported by Meiji Seika

Lexicon Genetics drug target may have potential in arthritis and autoimmune disease

Duloxetine reported safe and effective in major depressive disorder

Phase III trial evaluates E2F Decoy for prevention of coronary artery bypass graft failure

Extensive evaluation of once-daily methylphenidate (Concerta) in ADHD continues

New preclinical and clinical data on gepirone in major depression

WX-UK1 enters first clinical trial in cancer patients

Neurocrine Biosciences and Taisho restructure NBI-6024 agreement

PrimeBoost melanoma pharmaccine advances to phase II testing

MediGene and Evotec team up to form new company

Orphan drug grant will help defray the costs of clinical studies with MTC-DOX

Rheumatoid arthritis patients in need may receive adalimumab under the ACT program

Indications for Glucovance broadened by FDA

Novel oxazolidinones obtained at Versicor with expanded spectrum of antibacterial activity

Mechanism underlying contraceptive effect of ZK-137316 evaluated in monkeys

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...